Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis

doi:10.3748/wjg.v19.i40.6849

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 40

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7517)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

416

HTML

4315

Figures (1-2)

248

Tables (1-3)

210

Sum=5189

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1295

Download

1033

Sum=2328

Oct 28, 2013 (publication date) through Dec 29, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 28, 2013; 19(40): 6849-6856
Published online Oct 28, 2013. doi: 10.3748/wjg.v19.i40.6849

Table 1 Demography of the patients (mean ± SD)

	Non- antiviral (n = 38)	Antiviral (n = 79)	P value	Normal range
Gender (male/female)	30/8	62/17	1.000
Age (yr)	51.8 ± 10.3	50.4 ± 8.8	0.443
Median Child-Pugh score	8	8	0.887
Previous grade of EV (0/1/2/3)	21/0/6/11	41/4/18/16	0.330
Previous copies of HBVDNA (log10)	4.2 ± 1.1	4.6 ± 2.5	0.176	(-)
Previous hepatitis B e antigen (+/-)	24/14	46/33	0.689	(-)
Previous diameter of portal vein (mm)	11.8 ± 2.1	12.6 ± 2.2	0.392	< 10
Previous splenic section area (cm²)	35.3 ± 9.5	37.4 ± 13.2	0.384	< 20
GPT (IU/L)	49.7 ± 21.1	53.3 ± 64.9	0.315	5-40
GOT (IU/L)	48.1 ± 32.8	57.9 ± 56.2	0.231	5-40
TB (mmol/L)	26.7 ± 14.6	25.1 ± 15.5	0.635	3.4-17.1
ALB (g/L)	24.7 ± 4.9	25.4 ± 5.0	0.667	35-50
PT (s)	14.9 ± 2.5	16.5 ± 7.9	0.236	< 12
PLT (10¹²/L)	83.1 ± 41.8	78.7 ± 41.9	0.600	100-300
Endoscopic eradication (yes/no)	17/21	37/42	0.846
Propranolol (yes/no)	30/8	65/14	0.801

EV: Esophageal varices; HBV DNA: Hepatitis B virus DNA; GPT: Glutamic-pyruvic transaminase; GOT: Glutamic-oxaloacetic transaminase; TB: Total bilirubin; ALB: Serum albumin; PT: Prothrombin time; PLT: Platelet count.

Table 2 Laboratory examination results, portal diameter and splenic area in antiviral and non-antiviral groups during the study (mean ± SD)

	Non-antiviral	Antiviral	P value
	(n = 38)	(n = 79)
GPT (IU/L)	19.2 ± 53.1	-28.6 ± 58.8	< 0.001
GOT (IU/L)	19.9 ± 52.8	-34.9 ± 86.2	0.001
TB (mmol/L)	3.9 ± 9.6	-3.8 ± 9.5	0.009
ALB (g/L)	-2.8 ± 5.5	1.2 ± 6.1	0.003
PT (s)	1.4 ± 2.2	-0.2 ± 2.1	0.001
PLT (10¹²/L)	-18.9 ± 28.8	-10.3 ± 16.9	0.029
Diameter of portal vein (mm)	1.0 ± 0.9	0.2 ± 0.8	< 0.001
Splenic section area (cm²)	8.6 ± 7.2	3.6 ± 9.8	0.012

GPT: Glutamic-pyruvic transaminase; GOT: Glutamic-oxaloacetic transaminase; TB: Total bilirubin; ALB: Serum albumin; PT: Prothrombin time; PLT: Platelet count.

Table 3 Increase in score of varices/year in antiviral and non-antiviral therapy

	Non-antiviral	Antiviral	P value
All the cases (n = 117)	1.7 ± 1.2	1.0 ± 1.3	0.003
Endoscopic eradication (n = 63)	1.8 ± 1.5	1.1 ± 1.6	0.098
No endoscopic intervention (n = 54)	1.6 ± 0.7	0.8 ± 0.9	0.003

Citation: Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol 2013; 19(40): 6849-6856
URL: https://www.wjgnet.com/1007-9327/full/v19/i40/6849.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i40.6849